title: CYT107 enters Phase II clinical trial in HIV-infected patients.
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002908:Chronic Disease; D017322:Clinical Trials, Phase II as Topic; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D015851:Interleukin-7 / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; C508605:IL7 protein, human; D015851:Interleukin-7; D011994:Recombinant Proteins